Literature DB >> 23274364

High-performance liquid chromatography and coulometric electrode array detector in serum 25-hydroxyvitamin D(3) and 25-hydroxyvitamin D(2) analyses.

Tarja Nurmi1, Tomi-Pekka Tuomainen, Jyrki Virtanen, Jaakko Mursu, Sari Voutilainen.   

Abstract

The diode array detector in our high-performance liquid chromatography (HPLC) method for 25-hydroxyvitamin D(3) (25OHD(3)) and 25-hydroxyvitamin D(2) (25OHD(2)) did not perform satisfactorily for measuring human serum concentrations below 30nM. Because of a need for a reliable self-managed method in ongoing and starting vitamin D studies of the laboratory, we decided to develop a chromatographic method applying coulometric electrode array detector (CEAD) and evaluate reliability of the method by participating in the Vitamin D External Quality Assessment Scheme (DEQAS). The limit of quantification for 25OHD(3) and 25OHD(2) of the new method was 0.36pmol on column (3.6nM), and linearity ranged from 5 to 2400nM. Accuracy of the method was 90% for 25OHD(3) and 69% for 25OHD(2). The HPLC-CEAD results from five DEQAS rounds were in line with those of the other participating laboratories using HPLC methods. The HPLC-CEAD results for 25OHD(3) also corresponded to the results obtained with the Chromsystems HPLC method in a certified laboratory. The long-term coefficients of variation for 25OHD(3) were 6.2%, 7.8%, 5.2%, 6.7%, and 7.3% in concentrations of 27.5, 38.7, 48.4, 78.4, and 88.0nM, respectively. The developed HPLC-CEAD method was shown to be applicable for determining 25OHD(3) and 25OHD(2) in human serum samples.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23274364     DOI: 10.1016/j.ab.2012.12.010

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  7 in total

1.  The association between serum 25-hydroxyvitamin D3 concentration and risk of disease death in men: modification by magnesium intake.

Authors:  Jaakko Mursu; Tarja Nurmi; Sari Voutilainen; Tomi-Pekka Tuomainen; Jyrki K Virtanen
Journal:  Eur J Epidemiol       Date:  2015-03-12       Impact factor: 8.082

2.  Glucose Metabolism Effects of Vitamin D in Prediabetes: The VitDmet Randomized Placebo-Controlled Supplementation Study.

Authors:  Tomi-Pekka Tuomainen; Jyrki K Virtanen; Sari Voutilainen; Tarja Nurmi; Jaakko Mursu; Vanessa D F de Mello; Ursula Schwab; Martti Hakumäki; Kari Pulkki; Matti Uusitupa
Journal:  J Diabetes Res       Date:  2015-05-27       Impact factor: 4.011

3.  Primary vitamin D target genes allow a categorization of possible benefits of vitamin D₃ supplementation.

Authors:  Carsten Carlberg; Sabine Seuter; Vanessa D F de Mello; Ursula Schwab; Sari Voutilainen; Kari Pulkki; Tarja Nurmi; Jyrki Virtanen; Tomi-Pekka Tuomainen; Matti Uusitupa
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

4.  Relevance of vitamin D receptor target genes for monitoring the vitamin D responsiveness of primary human cells.

Authors:  Maja Vukić; Antonio Neme; Sabine Seuter; Noora Saksa; Vanessa D F de Mello; Tarja Nurmi; Matti Uusitupa; Tomi-Pekka Tuomainen; Jyrki K Virtanen; Carsten Carlberg
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

Review 5.  Measurement of circulating 25-hydroxyvitamin D: A historical review.

Authors:  C Le Goff; E Cavalier; J-C Souberbielle; A González-Antuña; E Delvin
Journal:  Pract Lab Med       Date:  2015-05-12

6.  Low serum 25-hydroxyvitamin D is associated with higher risk of frequent headache in middle-aged and older men.

Authors:  Jyrki K Virtanen; Rashid Giniatullin; Pekka Mäntyselkä; Sari Voutilainen; Tarja Nurmi; Jaakko Mursu; Jussi Kauhanen; Tomi-Pekka Tuomainen
Journal:  Sci Rep       Date:  2017-01-03       Impact factor: 4.379

7.  How competing risks affect the epidemiological relationship between vitamin D and prostate cancer incidence? A population-based study.

Authors:  Ari Voutilainen; Jyrki K Virtanen; Sari Hantunen; Tarja Nurmi; Petra Kokko; Tomi-Pekka Tuomainen
Journal:  Andrologia       Date:  2022-02-28       Impact factor: 2.532

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.